Disable all preview features

Health : Medical Research

The Scripps Research Institute

Today's research, tomorrow's cures

three stars

89.86

10550 North Torrey Pines Road TPC2
La Jolla, CA 92037
tel: (800) 788-4931   Web Site
EIN: 33-0435954

Board Leadership
John Diekman
Chairman of the Board

CEO
Peter G. Schultz
Chief Executive Officer

 
 
  Score
(out of 100)
Rating
Overall Score & Rating 89.86 three stars
  Financial 87.50 three stars
  Accountability & Transparency 93.00 four stars
This rating was published 03/01/2018 and includes data from FY2016, the most recent 990 received at that time.

Established in 1946, The Scripps Research Institute (TSRI) is one of the country's largest, private, non-profit research organizations. TSRI has always stood at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. TSRI has become internationally recognized for its basic research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology and synthetic vaccine development. The Institute has established a lengthy track record of major contributions to the betterment of health and the human condition.

Established in 1946, The Scripps Research Institute (TSRI) is one of the country's largest, private, non-profit research organizations. TSRI has always stood at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. TSRI has become internationally recognized for its basic research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology and synthetic vaccine development. The Institute has established a lengthy track record of major contributions to the betterment of health and the human condition.

Results Information

Program Name: Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC)
Problem

The current approach for medical discovery is constricted by a dogmatic unidirectional pipeline, fueled by labs working in isolation and secret competition. This limits opportunities for discovery and has resulted in a failure to respond in time to growing medical crises like Ebola virus. The revolutionary VIC collaboration now unites, rather than divides, the world’s researchers into a singular, parallel effort, leveraging diverse talents to forecast and fight growing threats to global health.

Strategy

Antibodies from academic and for-profit laboratories around the world have been gathered and de-identified in a single location. Identical boxes of the world's antibodies are then sent out to multiple researchers in the field, for parallel analysis. The result is a massive, multidisciplinary effort that has expedited identification of the most effective antibodies, the most effective combinations, and the most predictive laboratory tests to accelerate future research against other viruses.

IF:THEN

IF we can initiate a global field-wide collaboration in which all of the leading laboratories unite to develop the most efficacious antibody cocktail possible against Ebola virus,...

THEN we can more quickly and efficiently develop life-saving antibody therapeutics against the Ebola virus. This will help us be more prepared for the next Ebola outbreak, reduce the impact this disease has on human life and social, medical and economic systems in developing countries, and reduce the risk of this disease further spreading on a global scale.

IF we can develop a strategy in which antibodies could be sent from any laboratory to a single location where they would be de-identified and given a code name to be used throughout the study; thereby leveraging the resources and expertise of multiple labs to have an unbiased and fair method to perform the most statistically significant analysis of the largest antibody sample size possible;...

THEN each participating laboratory could contribute their strengths in analytical techniques to identify, characterize, and validate of antibodies against the filoviridae family to develop the most maximally effective treatment from combinations of rare antibodies that may have never existed unless the antibodies were all in the same room studied together. This could also be done more quickly and efficiently as a result of collaboration.

IF this model of collaboration works to develop an antibody for the Ebola virus,...

THEN it could also be used to develop life-saving antibody therapeutics against some of the world’s deadliest and most neglected viruses, like Lassa virus for example.

IF we can help scientists, universities and companies to join forces to treat these deadly diseases,...

THEN we could try to develop a sustainable model by licensing of the VIC therapies to First World organizations who can afford them, and use of licensing fees to support donation of therapies to patients in developing nations, who bear the greatest health, social and economic burden of emerging infectious disease.
Did you find the Results Information useful?
There was a problem saving your response. Please try again.
Thank you for your feedback. If you wish to share more about this data you may do so below.
Your feedback has been recorded
There was a problem saving your response. Please try again.
This results data is current as of November 2017, when it was provided to us by Classy. Results information published on this organization's rating page has no effect on its rating at this time. data iconLearn More

Financial

three stars

87.50

Accountability & Transparency

four stars

93.00

This rating was published 03/01/2018 and includes data from FY2016, the most recent 990 received at that time.
Overall Rating Chart
  Program Expenses
(Percent of the charity's total expenses spent on the programs
and services it delivers)
95.0%
  Administrative Expenses 4.0%
  Fundraising Expenses 0.8%
  Fundraising Efficiency < $0.01
  Working Capital Ratio (years) 1.54
  Program Expenses Growth -1.1%
  Liabilities to Assets 19.9%
All data for Financial Performance Metrics calculations was provided by The Scripps Research Institute on recent 990s filed with the IRS.
All data for Financial Performance Metrics calculations was provided by The Scripps Research Institute on recent 990s filed with the IRS.

Highly Rated

Charity Name & State Overall Score Overall Rating
The Scripps Research Institute (CA) 89.86 three stars
American Federation for Aging Research (NY) 92.92 four stars
International AIDS Vaccine Initiative (NY) 86.67 three stars
The Jackson Laboratory (ME) 93.16 four stars
McLaughlin Research Institute for Biomedical Sciences (MT) 91.18 four stars

Compare These Charities (Highly Rated)

REVENUE  
Contributions  
   Contributions, Gifts & Grants $80,130,277
   Federated Campaigns $0
   Membership Dues $0
   Fundraising Events $464,301
   Related Organizations $0
   Government Grants $242,488,856
Total Contributions $323,083,434
   Program Service Revenue $2,855,648
Total Primary Revenue $325,939,082
   Other Revenue $22,649,624
TOTAL REVENUE $348,588,706
   
EXPENSES  
   Program Expenses $346,440,010
   Administrative Expenses $15,441,959
   Fundraising Expenses $2,806,002
TOTAL FUNCTIONAL EXPENSES $364,687,971
   
Payments to Affiliates $0
Excess (or Deficit) for the year $-16,099,265
   
Net Assets $637,000,978

Program names and associated costs are listed for the top programs as reported on the charity's most recently filed Form 990. The top programs displayed will include the largest three programs, or those programs covering at least 60% of the charity's total expenses, whichever comes first.

Program Name Amount Spent % of Program Expenses
Research $325,935,674 94.1%
Education $20,504,336 5.9%

Ratings History

Form 990 FYE Date Published Overall Score Overall Rating
CN 2.1
2016-09 03/01/2018 89.86 three stars
2015-09 03/01/2017 91.67 four stars
2014-09 06/01/2016 94.30 four stars
 
CN 2.0
2014-09 04/01/2016 89.26 three stars
2014-09 12/22/2015 88.37 three stars
2013-09 06/01/2015 83.50 three stars
2012-09 03/01/2014 89.44 three stars
2011-09 11/06/2012 97.20 four stars
2010-09 02/01/2012 94.32 four stars
2009-09 09/20/2011 91.79 four stars
 
CN 1.0
2009-09 12/01/2010 88.48 three stars
2008-09 03/01/2010 89.55 three stars
2007-09 04/01/2009 91.49 four stars
2006-09 05/01/2008 98.37 four stars
2005-09 12/15/2006 95.47 four stars
2004-09 02/01/2006 95.66 four stars
2003-09 01/05/2005 95.13 four stars
2002-09 12/01/2003 96.43 four stars
2001-09 02/05/2003 96.59 four stars
2000-09 10/15/2002 99.50 four stars

The data displayed on this tab is provided by the IRS in the form of Publication 78 and the Business Master File (BMF).

EIN 33-0435954
Name in IRS Master File SCRIPPS RESEARCH INSTITUTE
NTEE Code H92
NTEE Classification Biomedicine, Bioengineering Research
NTEE Type Medical Research
Classification Scientific Organization
Subsection 501(c)(3)  (View the list of codes)
Activities (150) Hospital
(161) Scientific research (diseases)
(162) Other medical research
Foundation Status Hospital or medical research organization 170(b)(1)(A)(iii)
Deductibility Contributions are deductible
Affiliation Independent - the organization is an independent organization or an independent auxiliary (i.e., not affiliated with a National, Regional, or Geographic grouping of organizations).
Group Name [Not Applicable]
Ruling Date January, 1991
Filing Requirement 990 (all other) or 990EZ return
Fiscal Year End September
IRS Forms 990
(provided courtesy of Foundation Center)
(Log In or Register Now to View Forms 990!)
  • September, 2016
  • September, 2015
  • September, 2014
  • September, 2013
  • September, 2012

The data displayed in this profile is provided by the IRS for free in the form of Publication 78 and the Business Master File (BMF).

Compensation % of Expenses Paid to Title
$295,219 0.08% Peter G. Schultz President, CEO
Other Salaries of Note
$1,316,151 0.36% Michael A. Marletta Past President
$600,694 0.16% Richard A. Lerner Professor
$461,195 0.12% Jim C. Paulson Past President
$74,638 0.02% Steve A. Kay President

Highly Rated

Charity Name & State Overall Score Overall Rating
The Scripps Research Institute (CA) 89.86 three stars
Salk Institute for Biological Studies (CA) 90.71 four stars
Foundation for the National Institutes of Health (MD) 92.92 four stars
McLaughlin Research Institute for Biomedical Sciences (MT) 91.18 four stars
Oklahoma Medical Research Foundation (OK) 93.94 four stars

Compare These Charities (Highly Rated)

This charity has an official representative registered with Charity Navigator.

Charity Contact Info

The Scripps Research Institute
10550 North Torrey Pines Road
TPC2
La Jolla, CA 92037
tel: (800) 788-4931
fax: (858) 784-2608
EIN: 33-0435954

Visit Web Site

Board Leadership

John Diekman
Chairman of the Board

CEO

Peter G. Schultz
Chief Executive Officer

Join Our Mailing List

Join over 400,000 other informed givers and get updates on charity ratings, new features, hot topics, and tips for donating.